Destiny Pharma PLC Secondary endpoint analysis from Phase 2b trial (1232H)
02 Agosto 2021 - 01:00AM
UK Regulatory
TIDMDEST
RNS Number : 1232H
Destiny Pharma PLC
02 August 2021
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Update on secondary endpoint analysis from recent positive Phase
2b trial
Cardiac surgery patients receiving XF-73 nasal gel exhibited a
valuable,
sustained nasal reduction of Staphylococcus aureus
Brighton, United Kingdom, 2(nd) August 2021 - Destiny Pharma plc
(AIM: DEST), a clinical stage innovative biotechnology company
focused on the development of novel medicines that can prevent life
threatening infections is pleased to announce additional, strong
data from its recent Phase 2b clinical trial. In March 2021, the
Company announced that this study had met its primary endpoint,
demonstrating a highly significant reduction of 2.5 log (>99%)
in nasal Staphylococcus aureus immediately prior to surgery
compared to placebo (p<0.0001) after just 24 hours of XF-73
nasal gel dosing. The placebo-treated patients showed only a 0.4
log reduction in bacterial load immediately before surgery. All
patients in the study also received antibiotic dosing as standard
of care.
Today's additional data shows that XF-73 dosed patients can also
benefit from a sustained bacterial reduction at the three
post-surgical sample time points after wound closure of 1 hour, 2
and 6 days demonstrating 2.5 log, 2.4 log and 2.8 log reductions,
respectively, and sustaining the drop of over 99% in S. aureus
nasal burden. The placebo treated patients reported 0.4 log, 1.5
log and 2.5 log reductions at the same time points. The bacterial
reductions in XF-73 treated patients were shown to be highly
statistically significant over placebo at the 1 hour and 2 days
post-surgery timepoints (p<0.0001 and p<0.003, respectively).
As a result of the antibiotic dosing used as standard of care, the
6-day time point reduction in the placebo group were equivalent to
the XF-73 arm which was expected as it is known (*Wilson et al,
1977) that pre- and post-surgical systemic anti-staphylococcal
antibiotic dosing elicits a slow, gradual reduction in nasal
bacterial carriage.
This sustained nasal microbiological effect in the period of
greatest risk (pre-surgery to wound healing) of XF-73 in patients
is a desirable attribute for the reduction in the risk of acquiring
a post-surgical, staphylococcal infection. Today's new data
demonstrates that XF-73 nasal gel has the potential to keep
patients at a significantly low S. aureus nasal burden during the
period of highest infection risk which runs from 1 hour prior to
incision, during surgery itself, to the start of wound healing and
out to at least 6 days post-surgery.
Neil Clark, CEO of Destiny Pharma, said: "We are very pleased to
announce this additional, positive data from the successful Phase
2b study of XF-73 as a novel drug to reduce the incidence of
post-surgical infections such as MRSA. We are having discussions
with regulators in US and Europe to enable us to design the
required Phase 3 clinical study and will announce further updates
later in 2021. XF-73 has great potential to provide a safe, fast
acting medicine that kills S. aureus in the nose prior to surgery
thereby reducing patient infections whilst not generating bacterial
resistance. There is a clear clinical need for such a new medicine
that helps prevent post-surgical infections and there is a
significant commercial opportunity."
Scientific Advisory Board member , Professor Richard Proctor
(Professor Emeritus of Departments of Medical Microbiology &
Medicine at University of Wisconsin School of Medicine, Wisconsin,
US), said: " This new clinical data from the Phase 2b trial wherein
XF-73 produces a sustained reduction in nasal burden of S. aureus
out to at least 6 days is an important observation for several
reasons. First, nasal S. aureus burden directly correlates with the
incidence of post-surgical wound infections. Second, reduction in
S. aureus nasal colonization is associated with decreased numbers
of all staphylococcal infections ."
*Wilson et al., In vivo effects of josamycin, erythromycin, and
placebo therapy on nasal carriage of Staphylococcus aureus.
Antimicrobial Agents and Chemotherapy,1977, 3: p. 407-10)
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
Optimum Strategic Communications
Mary Clark / Hollie Vile / Manel Mateus
DestinyPharma@optimumcomms.com
+44 (0) 0203 174 1789
finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 207 220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2b clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
research projects.
For further information, please visit www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESBSGDRIGXDGBG
(END) Dow Jones Newswires
August 02, 2021 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024